ProCE Banner Activity

Emerging Therapies and the Near Future Evolution in Prostate Cancer: Expert Discussion of Frequently Asked Questions

Clinical Thought

In this commentary, expert faculty address audience questions from a live symposium on emerging therapies in prostate cancer.

Released: April 01, 2023



Neeraj Agarwal

Neeraj Agarwal, MD

Professor of Medicine
Senior Director for Clinical Research Innovation, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)

Tanya B. Dorff

Tanya B. Dorff, MD

Professor of Medicine
City of Hope National Medical Center
Department of Medical Oncology and Therapeutics Research
Section Chief, Genitourinary Cancer Program
Duarte, California

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Provided by

ProCE Banner


This activity is supported by an educational grant from

Exelixis, Inc.


Pfizer, Inc.

Faculty Disclosure

Neeraj Agarwal, MD, FASCO: advisor: Avea, Exelixis, Foundation Medicine, Gilead Sciences, Lilly, Merck.

Tanya B. Dorff, MD: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Sanofi, SeaGen.

Rana R. McKay, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Lilly, Merck, Myovant, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, Tempus; researcher: AstraZeneca, Bayer, Tempus.